CBLL Healthcare

CeriBell, Inc.

$28.27+4.86%

Price as of close on Nov 3, 2026 · Financials updated Oct 6, 2026

Basics

Sector: Healthcare
Industry: Medical Devices
Country: United States
Market cap: 1.1B USD
Enterprise value: 851.7M USD
Full-time employees: 327

Overall health

Strength: growing faster than most peersgrowing faster than peers
Strength: lower risk than most peers: more short-term liquiditylower risk: more liquidity
Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Ranks #625 of 1,157 healthcare companies (bottom 47%)

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, CeriBell looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Growing fast, still losing money. Revenue grew faster than 86% of peers, at an operating loss.
Revenue grew faster than 86% of peers, but the business runs at an operating loss (margin -69%).

StockQuotient Score

50/ 100

Oct 5 50 → Nov 4 50

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-6.1%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-7.1%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-5.0%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield11.8%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

84/100

Strong

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

12-month revenue up 7.3%

Why

Stronger than most peers on:

▲ 3-yr revenue
▲ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

The loss per share widened33% base weight · Z-score -1.20Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth50.9%

Yahoo Finance fallback · SEC figure unavailable or out of date · 3 fiscal years to Dec 2025Reported value33% base weight · Z-score 5.36Sector median: 0.0584 · MAD: 0.0840

Revenue growth31.7%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 2.63Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

16/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ ROA
▼ ROIC
▼ Operating margin

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-68.6%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -6.22Sector median: 0.0706 · MAD: 0.1217

Return on assets-39.7%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -7.70Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-47.8%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -5.23Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin88.9%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-51.4%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

2/3 inputs reported · Partial data

Since last quarter: No major change

Why

Stronger than most peers on:

▲ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

BetaUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.6250 · MAD: 0.3380

Current ratio9.18×

SEC filings · latest balance sheetReported value33% base weight · Z-score 4.76Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.16×

SEC filings · latest balance sheetReported value33% base weight · Z-score 0.32Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about CeriBell

Is CeriBell getting weaker?: Its latest SEC filing (Aug 10, 2026) showed no major changes. Its overall score is unchanged at 50/100 since Oct 28, 2026.
How is CeriBell valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -6.1% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -6.1% vs peers 1.5% (weaker than 100% of peers).
Is CeriBell growing?: Yes, faster than most of its peers. Growth scores 84/100 against 1,393 healthcare peers. 3-year revenue growth 50.9% vs a peer median of 5.8% (stronger than 93% of peers).3-year revenue growth 50.9% vs peers 5.8% (stronger than 93% of peers).
How profitable is CeriBell?: Less profitable than most of its peers. Profitability scores 16/100 against 1,393 healthcare peers. Return on assets -39.7% vs a peer median of 1.7% (weaker than 90% of peers).Return on assets -39.7% vs peers 1.7% (weaker than 90% of peers).
How risky is CeriBell?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 9.18× vs a peer median of 2.59× (stronger than 86% of peers).Current ratio 9.18× vs peers 2.59× (stronger than 86% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 10, 2026 · compared with the quarter ended Mar 31, 2026

No major changes

Worth watching: CeriBell is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous quarter	Latest quarter	Change
Revenue (12 months)	95.1M USD	102.0M USD	+7.3%
Net income (12 months)	−60.4M USD	−66.0M USD	+9.3%
Operating margin	-68.3%	-68.6%	−0.3 pts
Free cash flow (12 months)	−49.4M USD	−54.7M USD	+10.7%
Debt	19.9M USD	20.0M USD	+0.3%
Cash	45.3M USD	32.7M USD	−27.8%
Shares outstanding	37.9M	38.4M	+1.1%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Medical Devices · 33 companies

Valuations in Medical Devices are near the bottom of their range since 2016.

7% of months since 2016 were valued lower than now.
4% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values −8% and earnings +33% (medians): earnings grew faster than prices.
Median price-to-sales is +20% vs the whole market, against a usual +109%.

2016Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2023	FY 2024	FY 2025	Change
Gross margin	84.4%	86.7%	87.9%	▲ 1.2 pts
Operating margin	-66.4%	-60.7%	-65.6%	▼ 4.9 pts
Net margin	-65.1%	-61.8%	-60.0%	▲ 1.8 pts
Return on assets (ROA)	-50.0%	-17.9%	-27.3%	▼ 9.3 pts
Return on equity (ROE)	—	-21.2%	-34.4%	▼ 13 pts
Free cash flow margin	-66.6%	-55.6%	-46.7%	▲ 8.9 pts
Current ratio	2.41×	16.73×	9.73×	▼ 42%
Quick ratio	2.13×	16.19×	9.35×	▼ 42%
Debt to equity	—	0.10×	0.13×	▲ 25%
Interest coverage	-14.32×	-19.93×	-30.90×	▼ 55%

CBLL price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: growing faster than most peersgrowing faster than peers

Strength: lower risk than most peers: more short-term liquiditylower risk: more liquidity

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Ranks #625 of 1,157 healthcare companies (bottom 47%)

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, CeriBell looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Growing fast, still losing money. Revenue grew faster than 86% of peers, at an operating loss.

Revenue grew faster than 86% of peers, but the business runs at an operating loss (margin -69%).

Questions investors ask about CeriBell

Is CeriBell getting weaker?

Its latest SEC filing (Aug 10, 2026) showed no major changes. Its overall score is unchanged at 50/100 since Oct 28, 2026.

How is CeriBell valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -6.1% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -6.1% vs peers 1.5% (weaker than 100% of peers).

Is CeriBell growing?

Yes, faster than most of its peers. Growth scores 84/100 against 1,393 healthcare peers. 3-year revenue growth 50.9% vs a peer median of 5.8% (stronger than 93% of peers).3-year revenue growth 50.9% vs peers 5.8% (stronger than 93% of peers).

How profitable is CeriBell?

Less profitable than most of its peers. Profitability scores 16/100 against 1,393 healthcare peers. Return on assets -39.7% vs a peer median of 1.7% (weaker than 90% of peers).Return on assets -39.7% vs peers 1.7% (weaker than 90% of peers).

How risky is CeriBell?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 9.18× vs a peer median of 2.59× (stronger than 86% of peers).Current ratio 9.18× vs peers 2.59× (stronger than 86% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

95.1M USD

102.0M USD

+7.3%

Net income (12 months)

−60.4M USD

−66.0M USD

+9.3%

Operating margin

-68.3%

-68.6%

−0.3 pts

Free cash flow (12 months)

−49.4M USD

−54.7M USD

+10.7%

Debt

19.9M USD

20.0M USD

+0.3%

Cash

45.3M USD

32.7M USD

−27.8%

Shares outstanding

37.9M

38.4M

+1.1%

Key ratios

FY 2023

FY 2024

FY 2025

Change

Gross margin

84.4%

86.7%

87.9%

▲ 1.2 pts

Operating margin

-66.4%

-60.7%

-65.6%

▼ 4.9 pts

Net margin

-65.1%

-61.8%

-60.0%

▲ 1.8 pts

Return on assets (ROA)

-50.0%

-17.9%

-27.3%

▼ 9.3 pts

Return on equity (ROE)

—

-21.2%

-34.4%

▼ 13 pts

Free cash flow margin

-66.6%

-55.6%

-46.7%

▲ 8.9 pts

Current ratio

2.41×

16.73×

9.73×

▼ 42%

Quick ratio

2.13×

16.19×

9.35×

▼ 42%

Debt to equity

—

0.10×

0.13×

▲ 25%

Interest coverage

-14.32×

-19.93×

-30.90×

▼ 55%